Morgan Stanley analyst Ricky Goldwasser took a closer look at the potential take out value for Diplomat Pharmacy after the company said it is engaged in advanced discussions and has seen interest in both the whole company and its businesses, leading her to increase her "bull case scenario" value of the stock to $6 from $5. The specialty infusion business "has been the bright light in Diplomat's portfolio" and it could potentially be valued at $4 per share in a take out scenario, estimates Goldwasser. Recent industry conversations raise questions about what price a potential buyer would be willing to pay for the company's core specialty business, which could be worth $2 per share "depending on who the ultimate buyer is," Goldwasser added. She maintains an Equal Weight rating and $4 price target on Diplomat shares.